Alimera Sciences Inc.

5.25-0.2500-4.55%Vol 8.17K1Y Perf -40.15%
Jun 24th, 2022 16:00 DELAYED
BID2.20 ASK6.10
Open5.32 Previous Close5.50
Pre-Market- After-Market-
 - -  - -%
Target Price
8.00 
Analyst Rating
Strong Buy 1.00
Potential %
52.38 
Finscreener Ranking
★★★     50.44
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★★★+     52.32
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★★+     47.28
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
22.39 
Earnings Rating
Strong Sell
Market Cap36.76M 
Earnings Date
12th Aug 2022
Alpha-0.01 Standard Deviation0.21
Beta1.48 

Today's Price Range

5.215.57

52W Range

3.949.79

5 Year PE Ratio Range

-3.805.80

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.60%
1 Month
-13.22%
3 Months
-11.62%
6 Months
-3.67%
1 Year
-40.15%
3 Years
-61.96%
5 Years
-74.64%
10 Years
-89.10%

TickerPriceChg.Chg.%
ALIM5.25-0.2500-4.55
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.67-0.85-26.87
Q04 2021-0.38-0.59-55.26
Q03 2021-0.52-0.60-15.38
Q02 20211.250.76-39.20
Q01 2021-0.50-0.63-26.00
Q04 2020-0.09-0.18-100.00
Q03 2020-0.49-0.1275.51
Q02 2020-2.14-0.5176.17
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.61-12.96Negative
9/2022 QR-0.389.52Positive
12/2022 FY-2.08-10.05Negative
12/2023 FY-0.75--
Next Report Date12th Aug 2022
Estimated EPS Next Report-0.61
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume8.17K
Shares Outstanding7.00K
Shares Float4.47M
Trades Count109
Dollar Volume43.52K
Avg. Volume16.49K
Avg. Weekly Volume6.97K
Avg. Monthly Volume18.22K
Avg. Quarterly Volume24.30K

Alimera Sciences Inc. (NASDAQ: ALIM) stock closed at 5.25 per share at the end of the most recent trading day (a -4.55% change compared to the prior day closing price) with a volume of 8.17K shares and market capitalization of 36.76M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 127 people. Alimera Sciences Inc. CEO is Richard S. Eiswirth.

The one-year performance of Alimera Sciences Inc. stock is -40.15%, while year-to-date (YTD) performance is 2.34%. ALIM stock has a five-year performance of -74.64%. Its 52-week range is between 3.94 and 9.79, which gives ALIM stock a 52-week price range ratio of 22.39%

Alimera Sciences Inc. currently has a PE ratio of -5.20, a price-to-book (PB) ratio of 12.98, a price-to-sale (PS) ratio of 0.63, a price to cashflow ratio of 32.80, a PEG ratio of 2.32, a ROA of -13.98%, a ROC of -% and a ROE of 22.63%. The company’s profit margin is -11.19%, its EBITDA margin is 3.10%, and its revenue ttm is $59.71 Million , which makes it $8.53 revenue per share.

Of the last four earnings reports from Alimera Sciences Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.61 for the next earnings report. Alimera Sciences Inc.’s next earnings report date is 12th Aug 2022.

The consensus rating of Wall Street analysts for Alimera Sciences Inc. is Strong Buy (1), with a target price of $8, which is +52.38% compared to the current price. The earnings rating for Alimera Sciences Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Alimera Sciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Alimera Sciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 21.06, ATR14 : 0.44, CCI20 : -70.26, Chaikin Money Flow : -0.15, MACD : -0.04, Money Flow Index : 37.24, ROC : -11.17, RSI : 45.62, STOCH (14,3) : 31.69, STOCH RSI : 0.30, UO : 41.68, Williams %R : -68.31), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Alimera Sciences Inc. in the last 12-months were: David Holland (Buy at a value of $20 392), James R. Largent (Buy at a value of $43 090), John Philip Jones (Buy at a value of $20 399), Richard S. Eiswirth (Buy at a value of $203 496)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
1 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Alimera Sciences Inc.

Alimera Sciences is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN(R) is Alimera's a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years. A $2B global market, DME is often treated with acute therapies when the fluid in the eye returns. ILUVIEN reduces the recurrence of edema leading to stable vision, with the benefit of continuous treatment due to the product's novel drug delivery technology.

CEO: Richard S. Eiswirth

Telephone: +1 678 990-5740

Address: 6120 Windward Parkway, Alpharetta 30005, GA, US

Number of employees: 127

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%37%

Bearish Bullish

69%31%

Bearish Bullish

67%33%

News

Stocktwits